Symbols / LSTA Stock $3.42 +7.55% Lisata Therapeutics, Inc.
LSTA (Stock) Chart
About
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Stock Fundamentals
Scroll to Statements| Market Cap | 30.89M | Enterprise Value | 14.68M | Income | -16.59M | Sales | 170.00K | Book/sh | 1.68 | Cash/sh | 1.77 |
| Dividend Yield | — | Payout | 0.00% | Employees | 21 | IPO | — | P/E | — | Forward P/E | -5.18 |
| PEG | 118.40 | P/S | 181.71 | P/B | 2.03 | P/C | — | EV/EBITDA | -0.81 | EV/Sales | 86.36 |
| Quick Ratio | 5.42 | Current Ratio | 5.76 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -1.91 | EPS next Y | -0.66 |
| EPS Growth | — | Revenue Growth | -90.00% | Earnings | 2026-05-07 | ROA | -43.15% | ROE | -75.53% | ROIC | — |
| Gross Margin | 100.00% | Oper. Margin | -30.79% | Profit Margin | 0.00% | Shs Outstand | 9.03M | Shs Float | 7.28M | Short Float | 0.22% |
| Short Ratio | 0.35 | Short Interest | — | 52W High | 5.07 | 52W Low | 1.81 | Beta | 1.11 | Avg Volume | 103.07K |
| Volume | 77.72K | Target Price | $9.50 | Recom | None | Prev Close | $3.18 | Price | $3.42 | Change | 7.55% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.50
Mean price target
2. Current target
$3.42
Latest analyst target
3. DCF / Fair value
$-21.63
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.42
Low
$4.00
High
$15.00
Mean
$9.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-21 | down | Brookline Capital | Buy → Hold | — |
| 2025-08-21 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-07-15 | main | Brookline Capital | Buy → Buy | $32 |
| 2024-12-11 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-11-21 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-09-18 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-08-13 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-07-19 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-07-10 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-06-14 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-05-21 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-04-26 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-04-25 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-03-01 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-01-04 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-05-25 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-03-31 | reit | HC Wainwright & Co. | — → Buy | $15 |
| 2022-10-19 | main | HC Wainwright & Co. | — → Buy | $15 |
- Lisata Therapeutics (LSTA) Market Dynamics | Lisata Therapeutics posts 10.2% EPS beat, 170B revenue - Retail Trader Ideas - UBND thành phố Hải Phòng hu, 23 Apr 2026 06
- LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders - Business Wire Wed, 21 Jan 2026 08
- Lisata investors offered $5 cash now, $1 more if certepetide gets filed - Stock Titan Fri, 06 Mar 2026 08
- Lisata Therapeutics Inc (LSTA) - Valuation Measures & Financial Statistics - GuruFocus Mon, 20 Apr 2026 09
- Lisata Therapeutics Delays Tender Offer Launch in Merger - The Globe and Mail Sat, 04 Apr 2026 07
- Lisata stock soars after Kuva Labs acquisition offer at 85% premium - Investing.com Wed, 21 Jan 2026 08
- Lisata Therapeutics (LSTA) Market Dynamics | Lisata Therapeutics posts 10.2% EPS beat, 170B revenue - Expert Entry Points - Xã Thanh Hà hu, 23 Apr 2026 03
- Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer - Yahoo Finance Wed, 21 Jan 2026 08
- Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders - PR Newswire Mon, 09 Mar 2026 07
- Lisata Therapeutics to Be Acquired by Kuva Labs - TipRanks Mon, 09 Mar 2026 07
- Lisata Shares Nearly Double On Buyout Offer: Here Are The Details - Stocktwits Wed, 21 Jan 2026 18
- Lisata Therapeutics And 2 Other Penny Stocks Worth Watching - simplywall.st hu, 22 Jan 2026 08
- Lisata Therapeutics (LSTA) and Kuva Labs delay tender offer launch to April 13 - Stock Titan hu, 02 Apr 2026 07
- Lisata Extends Kuva Labs Acquisition Term Sheet Timeline - The Globe and Mail Sat, 28 Feb 2026 08
- Lisata Therapeutics extends deadline for Kuva tender offer - TipRanks Wed, 15 Apr 2026 20
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.17
-83.00%
|
1.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.17
-83.00%
|
1.00
|
0.00
|
0.00
|
| Operating Expense |
|
18.38
-21.49%
|
23.41
-8.94%
|
25.71
-55.37%
|
57.60
|
| Research And Development |
|
7.95
-29.87%
|
11.33
-10.99%
|
12.73
-70.70%
|
43.46
|
| Selling General And Administration |
|
10.43
-13.62%
|
12.07
-6.93%
|
12.97
-8.25%
|
14.14
|
| General And Administrative Expense |
|
10.43
-13.62%
|
12.07
-6.93%
|
12.97
-8.25%
|
14.14
|
| Other Gand A |
|
10.43
-13.62%
|
12.07
-6.93%
|
12.97
-8.25%
|
14.14
|
| Total Expenses |
|
18.38
-21.49%
|
23.41
-8.94%
|
25.71
-55.37%
|
57.60
|
| Operating Income |
|
-18.21
+18.74%
|
-22.41
+12.83%
|
-25.71
+55.37%
|
-57.60
|
| Total Operating Income As Reported |
|
-18.21
+18.74%
|
-22.41
+12.83%
|
-25.71
+55.37%
|
-57.60
|
| EBITDA |
|
-18.06
+18.76%
|
-22.23
+12.87%
|
-25.52
+55.64%
|
-57.53
|
| Normalized EBITDA |
|
-18.87
+21.76%
|
-24.12
+14.61%
|
-28.24
+51.79%
|
-58.58
|
| Reconciled Depreciation |
|
0.15
-16.09%
|
0.17
-7.94%
|
0.19
+173.91%
|
0.07
|
| EBIT |
|
-18.21
+18.74%
|
-22.41
+12.83%
|
-25.71
+55.37%
|
-57.60
|
| Total Unusual Items |
|
0.81
-57.20%
|
1.88
-30.87%
|
2.72
+158.94%
|
1.05
|
| Total Unusual Items Excluding Goodwill |
|
0.81
-57.20%
|
1.88
-30.87%
|
2.72
+158.94%
|
1.05
|
| Net Income |
|
-16.59
+17.01%
|
-19.98
+4.10%
|
-20.84
+61.57%
|
-54.23
|
| Pretax Income |
|
-17.55
+15.57%
|
-20.78
+10.30%
|
-23.17
+59.14%
|
-56.70
|
| Other Income Expense |
|
0.66
-59.35%
|
1.63
-35.93%
|
2.54
+182.94%
|
0.90
|
| Other Non Operating Income Expenses |
|
-0.14
+43.58%
|
-0.26
-38.17%
|
-0.19
-20.00%
|
-0.15
|
| Gain On Sale Of Security |
|
0.81
-57.20%
|
1.88
-30.87%
|
2.72
+158.94%
|
1.05
|
| Tax Provision |
|
-0.96
-20.55%
|
-0.80
+65.75%
|
-2.33
+6.01%
|
-2.48
|
| Tax Rate For Calcs |
|
0.00
+42.77%
|
0.00
-61.82%
|
0.00
+130.02%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.04
-38.89%
|
0.07
-73.61%
|
0.27
+495.61%
|
0.05
|
| Net Income Including Noncontrolling Interests |
|
-16.59
+17.01%
|
-19.98
+4.10%
|
-20.84
+61.57%
|
-54.23
|
| Net Income From Continuing Operation Net Minority Interest |
|
-16.59
+17.01%
|
-19.98
+4.10%
|
-20.84
+61.57%
|
-54.23
|
| Net Income From Continuing And Discontinued Operation |
|
-16.59
+17.01%
|
-19.98
+4.10%
|
-20.84
+61.57%
|
-54.23
|
| Net Income Continuous Operations |
|
-16.59
+17.01%
|
-19.98
+4.10%
|
-20.84
+61.57%
|
-54.23
|
| Minority Interests |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Normalized Income |
|
-17.35
+20.41%
|
-21.80
+6.42%
|
-23.29
+57.83%
|
-55.23
|
| Net Income Common Stockholders |
|
-16.59
+17.01%
|
-19.98
+4.10%
|
-20.84
+61.57%
|
-54.23
|
| Diluted EPS |
|
-1.91
+20.42%
|
-2.40
+6.98%
|
-2.58
+75.36%
|
-10.47
|
| Basic EPS |
|
-1.91
+20.42%
|
-2.40
+6.98%
|
-2.58
+75.36%
|
-10.47
|
| Basic Average Shares |
|
8.69
+4.30%
|
8.33
+3.17%
|
8.07
+55.85%
|
5.18
|
| Diluted Average Shares |
|
8.69
+4.30%
|
8.33
+3.17%
|
8.07
+55.85%
|
5.18
|
| Diluted NI Availto Com Stockholders |
|
-16.59
+17.01%
|
-19.98
+4.10%
|
-20.84
+61.57%
|
-54.23
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
17.74
-49.31%
|
35.00
-36.00%
|
54.69
-25.11%
|
73.03
|
| Current Assets |
|
17.70
-48.80%
|
34.58
-35.88%
|
53.92
-24.98%
|
71.88
|
| Cash Cash Equivalents And Short Term Investments |
|
15.96
-48.93%
|
31.25
-38.17%
|
50.53
-27.00%
|
69.23
|
| Cash And Cash Equivalents |
|
15.96
-1.56%
|
16.21
-28.26%
|
22.59
-29.74%
|
32.15
|
| Cash Equivalents |
|
—
|
—
|
16.71
-39.59%
|
27.67
|
| Cash Financial |
|
—
|
—
|
5.88
+31.03%
|
4.49
|
| Other Short Term Investments |
|
0.00
-100.00%
|
15.04
-46.19%
|
27.94
-24.63%
|
37.07
|
| Receivables |
|
0.00
-100.00%
|
0.90
|
0.00
|
—
|
| Accounts Receivable |
|
0.00
-100.00%
|
0.90
|
0.00
|
—
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
1.75
-28.20%
|
2.43
-28.21%
|
3.39
+27.89%
|
2.65
|
| Total Non Current Assets |
|
0.04
-90.33%
|
0.42
-44.94%
|
0.77
-33.51%
|
1.16
|
| Net PPE |
|
0.02
-75.00%
|
0.07
-58.86%
|
0.17
-40.88%
|
0.30
|
| Gross PPE |
|
0.49
-25.26%
|
0.66
+0.00%
|
0.66
-7.29%
|
0.71
|
| Accumulated Depreciation |
|
-0.48
+19.19%
|
-0.59
-21.19%
|
-0.49
-16.55%
|
-0.42
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
0.49
-16.13%
|
0.59
+0.00%
|
0.59
-4.07%
|
0.61
|
| Leases |
|
0.00
-100.00%
|
0.07
+0.00%
|
0.07
-27.27%
|
0.10
|
| Goodwill And Other Intangible Assets |
|
0.00
-100.00%
|
0.19
-27.00%
|
0.26
-21.26%
|
0.33
|
| Other Intangible Assets |
|
—
|
0.19
-27.00%
|
0.26
-21.26%
|
0.33
|
| Other Non Current Assets |
|
0.02
-85.63%
|
0.16
-51.81%
|
0.33
-37.12%
|
0.53
|
| Total Liabilities Net Minority Interest |
|
3.14
-44.71%
|
5.68
-16.40%
|
6.80
+1.34%
|
6.71
|
| Current Liabilities |
|
3.07
-45.29%
|
5.61
-14.83%
|
6.59
+3.24%
|
6.38
|
| Payables And Accrued Expenses |
|
3.07
-43.92%
|
5.48
-14.73%
|
6.42
+3.53%
|
6.20
|
| Payables |
|
1.02
-20.64%
|
1.28
-46.96%
|
2.42
-8.81%
|
2.65
|
| Accounts Payable |
|
1.02
-20.64%
|
1.28
-46.96%
|
2.42
-8.81%
|
2.65
|
| Current Accrued Expenses |
|
2.05
-51.05%
|
4.19
+4.77%
|
4.00
+12.77%
|
3.55
|
| Current Debt And Capital Lease Obligation |
|
—
|
0.14
-18.45%
|
0.17
-6.67%
|
0.18
|
| Current Capital Lease Obligation |
|
0.00
-100.00%
|
0.14
-18.45%
|
0.17
-6.67%
|
0.18
|
| Total Non Current Liabilities Net Minority Interest |
|
0.07
+0.00%
|
0.07
-65.71%
|
0.21
-35.78%
|
0.33
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
—
|
0.30
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
—
|
0.30
|
| Other Non Current Liabilities |
|
0.07
+0.00%
|
0.07
-65.71%
|
0.21
-35.78%
|
0.33
|
| Stockholders Equity |
|
14.86
-49.76%
|
29.57
-38.58%
|
48.15
-27.68%
|
66.58
|
| Common Stock Equity |
|
14.86
-49.76%
|
29.57
-38.58%
|
48.15
-27.68%
|
66.58
|
| Capital Stock |
|
0.01
+12.50%
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
|
| Common Stock |
|
0.01
+12.50%
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
|
| Preferred Stock |
|
—
|
—
|
—
|
0.00
|
| Share Issued |
|
8.83
+5.05%
|
8.41
+3.18%
|
8.15
+3.16%
|
7.90
|
| Ordinary Shares Number |
|
8.83
+5.05%
|
8.41
+3.18%
|
8.15
+3.16%
|
7.90
|
| Treasury Shares Number |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Additional Paid In Capital |
|
580.24
+0.32%
|
578.42
+0.25%
|
576.97
+0.42%
|
574.55
|
| Retained Earnings |
|
-564.65
-3.03%
|
-548.07
-3.78%
|
-528.08
-4.11%
|
-507.24
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.04
+54.32%
|
-0.08
-92.86%
|
-0.04
-44.83%
|
-0.03
|
| Treasury Stock |
|
0.71
+0.00%
|
0.71
+0.00%
|
0.71
+0.00%
|
0.71
|
| Minority Interest |
|
-0.25
+0.00%
|
-0.25
+0.00%
|
-0.25
+0.00%
|
-0.25
|
| Other Equity Adjustments |
|
-0.04
+54.32%
|
-0.08
-92.86%
|
-0.04
-44.83%
|
-0.03
|
| Total Equity Gross Minority Interest |
|
14.60
-50.20%
|
29.32
-38.79%
|
47.89
-27.79%
|
66.32
|
| Total Capitalization |
|
14.86
-49.76%
|
29.57
-38.58%
|
48.15
-27.68%
|
66.58
|
| Working Capital |
|
14.63
-49.48%
|
28.96
-38.81%
|
47.33
-27.73%
|
65.49
|
| Invested Capital |
|
14.86
-49.76%
|
29.57
-38.58%
|
48.15
-27.68%
|
66.58
|
| Total Debt |
|
0.00
-100.00%
|
0.14
-18.45%
|
0.17
-6.67%
|
0.18
|
| Capital Lease Obligations |
|
0.00
-100.00%
|
0.14
-18.45%
|
0.17
-6.67%
|
0.18
|
| Net Tangible Assets |
|
14.86
-49.44%
|
29.38
-38.65%
|
47.88
-27.71%
|
66.24
|
| Tangible Book Value |
|
14.86
-49.44%
|
29.38
-38.65%
|
47.88
-27.71%
|
66.24
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-15.95
+17.60%
|
-19.36
+3.37%
|
-20.03
+5.38%
|
-21.17
|
| Cash Flow From Continuing Operating Activities |
|
-15.95
+17.60%
|
-19.36
+3.37%
|
-20.03
+5.38%
|
-21.17
|
| Net Income From Continuing Operations |
|
-16.59
+17.01%
|
-19.98
+4.10%
|
-20.84
+61.57%
|
-54.23
|
| Depreciation Amortization Depletion |
|
0.15
-16.09%
|
0.17
-7.94%
|
0.19
+173.91%
|
0.07
|
| Depreciation And Amortization |
|
0.15
-16.09%
|
0.17
-7.94%
|
0.19
+173.91%
|
0.07
|
| Other Non Cash Items |
|
—
|
—
|
—
|
30.39
|
| Stock Based Compensation |
|
1.23
-25.83%
|
1.65
-18.89%
|
2.04
-22.69%
|
2.64
|
| Provisionand Write Offof Assets |
|
0.50
|
0.00
|
—
|
—
|
| Asset Impairment Charge |
|
0.13
|
0.00
|
—
|
—
|
| Operating Gains Losses |
|
—
|
0.13
+4233.33%
|
0.00
|
—
|
| Gain Loss On Sale Of PPE |
|
—
|
0.00
-100.00%
|
0.00
|
0.00
|
| Change In Working Capital |
|
-1.29
-47.42%
|
-0.87
-88.96%
|
-0.46
+44.40%
|
-0.83
|
| Change In Receivables |
|
0.40
+144.56%
|
-0.90
|
0.00
|
—
|
| Changes In Account Receivables |
|
0.40
+144.56%
|
-0.90
|
0.00
|
—
|
| Change In Prepaid Assets |
|
0.74
-12.91%
|
0.85
+203.40%
|
-0.82
+2.49%
|
-0.84
|
| Change In Payables And Accrued Expense |
|
-2.57
-158.29%
|
-0.99
-1230.68%
|
0.09
+139.46%
|
-0.22
|
| Change In Payable |
|
-2.57
-158.29%
|
-0.99
-1230.68%
|
0.09
|
—
|
| Change In Account Payable |
|
-2.57
-158.29%
|
-0.99
-1230.68%
|
0.09
|
—
|
| Change In Other Current Assets |
|
0.14
-17.65%
|
0.17
-37.96%
|
0.27
+15.61%
|
0.24
|
| Investing Cash Flow |
|
15.09
+14.00%
|
13.23
+30.99%
|
10.10
-65.06%
|
28.91
|
| Cash Flow From Continuing Investing Activities |
|
15.09
+14.00%
|
13.23
+30.99%
|
10.10
-65.06%
|
28.91
|
| Net PPE Purchase And Sale |
|
-0.03
|
0.00
|
0.00
+100.00%
|
-0.28
|
| Purchase Of PPE |
|
-0.03
|
0.00
|
0.00
+100.00%
|
-0.28
|
| Capital Expenditure |
|
-0.03
|
—
|
—
|
-0.28
|
| Net Investment Purchase And Sale |
|
15.11
+13.10%
|
13.36
+32.28%
|
10.10
-68.93%
|
32.52
|
| Purchase Of Investment |
|
-9.18
+83.52%
|
-55.69
+43.45%
|
-98.48
-9.80%
|
-89.69
|
| Sale Of Investment |
|
24.29
-64.82%
|
69.05
-36.41%
|
108.58
-11.15%
|
122.20
|
| Net Business Purchase And Sale |
|
0.00
+100.00%
|
-0.13
|
0.00
|
—
|
| Purchase Of Business |
|
0.00
+100.00%
|
-0.13
|
0.00
|
—
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
-3.32
|
| Financing Cash Flow |
|
0.60
+390.78%
|
-0.21
-153.51%
|
0.39
+271.88%
|
-0.22
|
| Cash Flow From Continuing Financing Activities |
|
0.60
+390.78%
|
-0.21
-153.51%
|
0.39
+271.88%
|
-0.22
|
| Net Common Stock Issuance |
|
0.84
+1141.18%
|
0.07
-78.82%
|
0.32
+646.51%
|
0.04
|
| Proceeds From Stock Option Exercised |
|
0.01
|
0.00
-100.00%
|
0.15
|
0.00
|
| Net Other Financing Charges |
|
-0.25
+7.66%
|
-0.27
-201.10%
|
-0.09
+65.92%
|
-0.27
|
| Changes In Cash |
|
-0.26
+95.83%
|
-6.33
+33.69%
|
-9.54
-226.98%
|
7.52
|
| Effect Of Exchange Rate Changes |
|
0.01
+120.00%
|
-0.06
-243.75%
|
-0.02
-60.00%
|
-0.01
|
| Beginning Cash Position |
|
16.21
-28.26%
|
22.59
-29.74%
|
32.15
+30.46%
|
24.65
|
| End Cash Position |
|
15.96
-1.56%
|
16.21
-28.26%
|
22.59
-29.74%
|
32.15
|
| Free Cash Flow |
|
-15.98
+17.46%
|
-19.36
+3.37%
|
-20.03
+6.63%
|
-21.45
|
| Interest Paid Supplemental Data |
|
—
|
—
|
—
|
—
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
—
|
—
|
| Amortization Of Securities |
|
-0.07
+83.52%
|
-0.46
+52.60%
|
-0.96
-221.83%
|
0.79
|
| Common Stock Issuance |
|
0.84
+1141.18%
|
0.07
-78.82%
|
0.32
+646.51%
|
0.04
|
| Earnings Losses From Equity Investments |
|
0.00
-100.00%
|
0.13
|
0.00
|
—
|
| Issuance Of Capital Stock |
|
0.84
+1141.18%
|
0.07
-78.82%
|
0.32
+646.51%
|
0.04
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-15 View
- 8-K2026-04-03 View
- 10-K2026-03-12 View
- 8-K2026-03-09 View
- 8-K2026-02-27 View
- 8-K2026-01-27 View
- 8-K2026-01-21 View
- 42026-01-13 View
- 42026-01-13 View
- 42026-01-13 View
- 42026-01-13 View
- 42026-01-13 View
- 42026-01-13 View
- 42026-01-13 View
- 42026-01-13 View
- 42026-01-13 View
- 10-Q2025-11-06 View
- 8-K2025-11-06 View
- 8-K2025-10-14 View
- 8-K2025-10-08 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|